Solid phase extraction (SPE)
Collaboration leads to new antibody media
Aug 17 2010
G-CSF CaptureSelect is licensed to Octapharma for use in purifying recombinant human granulocyte-colony stimulating factor, or G-CSF.
Kim Bjornstrup, vice-chairman of Octapharma, explains that the two companies' previous work led to the development.
"The start of this collaboration with BAC, in G-CSF, came from the success with our previous collaboration to develop a ligand for the purification of factor IX," the spokesman says.
With the ligand, Octapharma aims to cut the downstream development time needed in order to produce the recombinant protein, as well as raising the overall recovery of the process compared with conventional techniques.
Octapharma was founded in 1983 and has grown to employ more than 4,000 people, with sales in 2009 surpassing the €1 billion (£820 million) benchmark.
Events
Jun 01 2025 Baltimore, MD, USA
Jun 15 2025 Bruges, Belgium
Jul 14 2025 Kuala Lumpur, Malaylsia
Jul 15 2025 Brighton, UK
ACS National Meeting - Fall 2025
Aug 17 2025 Washington DC, USA & Virtual